Author:
Shetty Anita K.,Desai Devak G.,Wilson Janice,Tyring Stephen K.
Publisher
Springer Berlin Heidelberg
Reference112 articles.
1. Otto, M.: New nucleoside reverse transcriptase inhibitors for the treatment of HIV infections. Curr. Opin. Pharmacol. 4(5), 431–436 (2004)
2. Waters, L., Nelson, M.: New drugs. HIV Med. 6(4), 225–231 (2005)
3. Otto, M., et al.: Single and multiple dose pharmacokinetics and safety of the nucleoside Racivir in male volunteers. In: Frontiers in Drug Development for Antiretroviral Therapies, Naples, FL, 2002
4. Herzmann, C., et al.: Safety, Pharmacokinetics, and Efficacy of (+/–)-{beta}-2’, 3’-Dideoxy-5-Fluoro-3’-Thiacytidine with Efavirenz and Stavudine in Antiretroviral-Naive Human Immunodeficiency Virus-Infected Patients. Antimicrob. Agents Chemother. 49(7), 2828 (2005)
5. Collins, P., et al.: Analysis of the genotypes of viruses isolated from patients after 10 days monotherapy with SPD754. In: 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2004